#1 Clinical Trials Search in Europe

Abelacimab

Abelacimab is an innovative anticoagulant drug currently being studied in several clinical trials for its potential in treating various medical conditions. These trials aim to evaluate the safety and effectiveness of Abelacimab in preventing blood clots and managing conditions such as atrial fibrillation and cancer-associated venous thromboembolism. The ongoing research seeks to determine if Abelacimab could provide better outcomes compared to existing treatments while maintaining a favorable safety profile.

Table of Contents

What is Abelacimab?

Abelacimab is a new medication being studied for its potential to prevent and treat blood clots and related conditions. It is classified as a biological product, which means it is derived from living organisms rather than being chemically synthesized[1]. Abelacimab is currently undergoing clinical trials to evaluate its safety and effectiveness in treating various conditions related to blood clotting.

How Does Abelacimab Work?

Abelacimab works by targeting a specific protein in the blood called Factor XI. This protein plays a crucial role in the blood clotting process. By inhibiting Factor XI, abelacimab may help prevent the formation of harmful blood clots while potentially having a lower risk of causing excessive bleeding compared to some other blood thinners[2].

What Conditions Does Abelacimab Treat?

Based on ongoing clinical trials, abelacimab is being studied for the treatment and prevention of several conditions:

  • Atrial Fibrillation: A heart rhythm disorder that increases the risk of stroke[1]
  • Venous Thromboembolism (VTE): A condition where blood clots form in the veins, often in the legs or lungs[3]
  • Cancer-Associated VTE: Blood clots that occur in cancer patients, particularly those with gastrointestinal or genitourinary cancers[4]

How is Abelacimab Administered?

Abelacimab is typically administered in two ways:

  1. Intravenous (IV) Infusion: An initial dose may be given through an IV line directly into the bloodstream.
  2. Subcutaneous Injection: Subsequent doses are often given as injections under the skin, which can be done monthly[1][3].

The exact dosing schedule and amount may vary depending on the condition being treated and the specific clinical trial protocol.

Ongoing Clinical Trials

Several phase 3 clinical trials are currently underway to evaluate abelacimab:

  • LILAC Study: Testing abelacimab in patients with atrial fibrillation who are unsuitable for oral anticoagulation[1]
  • AZALEA Study: Comparing abelacimab to rivaroxaban in patients with atrial fibrillation[2]
  • ASTER Study: Evaluating abelacimab versus apixaban for preventing blood clots in cancer patients[3]
  • MAGNOLIA Study: Comparing abelacimab to dalteparin in patients with gastrointestinal or genitourinary cancers who have experienced blood clots[4]

Potential Benefits of Abelacimab

Researchers are investigating whether abelacimab may offer several advantages over existing blood thinners:

  • Potentially lower risk of bleeding complications
  • Monthly dosing schedule, which could be more convenient for patients
  • Possible effectiveness in patients who cannot take other blood thinners
  • Potential for use in cancer patients at high risk of blood clots

Possible Side Effects

As abelacimab is still in clinical trials, the full range of potential side effects is not yet known. However, common side effects of blood thinners may include:

  • Bruising more easily
  • Prolonged bleeding from cuts
  • Nosebleeds
  • Gastrointestinal bleeding

The ongoing clinical trials are carefully monitoring patients for any adverse effects to establish the safety profile of abelacimab[1][2][3][4].

Important Considerations for Patients

If you are considering participating in a clinical trial for abelacimab or may be eligible for treatment in the future, keep in mind:

  • Abelacimab is still an investigational drug and not yet approved for general use.
  • Eligibility for clinical trials may depend on factors such as your medical history, current medications, and specific health conditions.
  • Always consult with your healthcare provider before considering any new treatment or participating in a clinical trial.
  • If you are pregnant, breastfeeding, or planning to become pregnant, inform your doctor as special considerations may apply[3][4].

As research on abelacimab continues, more information about its effectiveness and safety will become available. Patients with atrial fibrillation, a history of blood clots, or cancer-related clotting issues should stay informed about this potential new treatment option and discuss it with their healthcare providers.

Aspect Details
Drug Name Abelacimab
Drug Class Anticoagulant
Administration Intravenous (IV) followed by monthly subcutaneous injections
Conditions Studied Atrial Fibrillation, Cancer-associated Venous Thromboembolism
Trial Phases Phase 2 and Phase 3
Comparator Drugs Placebo, Rivaroxaban, Apixaban, Dalteparin
Primary Objectives Efficacy in preventing blood clots, Safety profile
Key Inclusion Criteria Adults with AF or cancer-associated VTE, specific risk scores
Key Exclusion Criteria Recent major bleeding, severe kidney dysfunction, certain cancers
Trial Designs Randomized, open-label, blinded endpoint evaluation

FAQ

  • What is Abelacimab? Abelacimab is a new anticoagulant drug being studied in clinical trials. It works by preventing blood clots and is being tested for various conditions such as atrial fibrillation and cancer-associated blood clots.
  • What medical conditions are being studied with Abelacimab? Abelacimab is being studied for atrial fibrillation (an irregular heart rhythm), venous thromboembolism (blood clots) in cancer patients, and for preventing blood clot recurrence in patients with gastrointestinal or genitourinary cancers.
  • How is Abelacimab administered? Abelacimab is typically administered through intravenous (IV) injection followed by monthly subcutaneous (under the skin) injections.
  • What are the potential benefits of Abelacimab over current treatments? The clinical trials aim to determine if Abelacimab is more effective or safer than current treatments like apixaban, rivaroxaban, or dalteparin in preventing blood clots and reducing bleeding risks.
  • Who can participate in Abelacimab clinical trials? Eligibility varies by study, but generally includes adults with specific medical conditions such as atrial fibrillation or cancer-associated blood clots. Each trial has specific inclusion and exclusion criteria that participants must meet.

Ongoing Clinical Trials on Abelacimab

  • Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Croatia Czechia Estonia Finland Germany +9

  • Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

    Not recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Czechia France Germany Hungary Ireland +6

  • Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

    Not recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Czechia France Germany Hungary Ireland +6

  • Study on the Safety and Tolerability of Abelacimab Compared to Rivaroxaban in Patients with Atrial Fibrillation

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Czechia Hungary Poland

Glossary

  • Abelacimab: A new anticoagulant drug being studied in clinical trials for preventing blood clots in various medical conditions.
  • Atrial Fibrillation (AF): An irregular and often rapid heart rhythm that can increase the risk of strokes, heart failure, and other heart-related complications.
  • Venous Thromboembolism (VTE): A condition where blood clots form in the veins, typically in the legs or lungs.
  • CHA2DS2-VASc Score: A clinical prediction score for estimating the risk of stroke in patients with atrial fibrillation.
  • Anticoagulation: The process of hindering the blood's ability to form clots, often used to prevent or treat blood clots.
  • DOAC: Direct Oral Anticoagulant, a type of blood-thinning medication taken by mouth.
  • Placebo: A substance with no active therapeutic effect, used as a control in clinical trials.
  • Randomized Trial: A study where participants are randomly assigned to different treatment groups to compare outcomes.
  • Open-label Study: A type of clinical trial where both the researchers and participants know which treatment is being administered.
  • Blinded Endpoint Evaluation: A method where the people assessing the outcomes of a trial are unaware of which treatment each participant received.
  • Creatinine Clearance: A test that measures how well your kidneys are working by estimating how much blood the kidneys can filter in a minute.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-abelacimab-for-high-risk-atrial-fibrillation-patients-unsuitable-for-oral-anticoagulation/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-abelacimab-compared-to-rivaroxaban-in-patients-with-atrial-fibrillation/
  3. http://clinicaltrials.eu/trial/study-comparing-abelacimab-and-apixaban-for-preventing-blood-clots-in-cancer-patients/
  4. http://clinicaltrials.eu/trial/study-on-abelacimab-and-dalteparin-for-preventing-blood-clots-in-patients-with-gastrointestinal-or-genitourinary-cancer/